The patient’s story began four months earlier with persistent watery diarrhea and recurrent abdominal discomfort that failed to respond to standard therapy for gastritis and duodenitis. Initial blood counts at a local hospital revealed a subtle but telling anomaly: an absolute monocyte count of 1.54 × 10⁹ per liter, above the normal threshold, together with a low platelet count of 66 × 10⁹ per liter. By the time he reached the referral center, his hemoglobin had fallen from 147 to 100 grams per liter, his platelets had dropped further to 62 × 10⁹ per liter, and his monocyte count had climbed to 1.93 × 10⁹ per liter. His spleen was enlarged, and his alkaline phosphatase — an enzyme normally kept below 125 units per liter — had skyrocketed to 1,145.3 units per liter, a biochemical red flag for infiltrative disease in bone and liver.

Imaging deepened the mystery. Contrast-enhanced computed tomography showed a spleen roughly 13 centimeters long studded with mildly enlarged retroperitoneal lymph nodes. Positron emission tomography using fluorodeoxyglucose revealed a gastric wall burning with metabolic activity at a maximum standardized uptake value of 19.1 — a figure more typical of aggressive lymphoma than of chronic indigestion — along with diffusely increased uptake in the spleen and mild hypermetabolism in mediastinal and abdominal nodes. Yet endoscopic biopsies of the stomach and duodenum showed only chronic active gastritis and ulcers, with no infiltrative lesions. The mismatch between spectacular metabolic signals and bland biopsy results pointed the team toward the bone marrow.

What they found there was extraordinary. The marrow biopsy showed dense, multifocal infiltrates of atypical mast cells consuming roughly half of the marrow cellularity, accompanied by grade MF-2 to MF-3 reticulin fibrosis. The aspirate smears told a more nuanced story: atypical mast cells made up 18.5 percent of nucleated cells, just under the 20 percent threshold that the current WHO classification requires for a diagnosis of mast cell leukemia. Because an adequate aspirate was available, the biopsy burden alone could not override that criterion, so the team classified the disease as advanced systemic mastocytosis rather than the leukemic variant. The mast cells displayed the classic aberrant phenotype — bright CD117 with inappropriate CD25 expression — and were positive for tryptase on immunohistochemistry.

Next-generation sequencing locked in the molecular diagnosis. The panel detected the KIT D816V mutation, the pathogenic engine of more than 90 percent of adult systemic mastocytosis cases, at a variant allele frequency of 12.1 percent. But the sequencing revealed far more than a mast-cell clone. A frameshift mutation in TET2 at 64.9 percent variant allele frequency marked a founding epigenetic clone, compounded by a deletion of TET2 exons 3 through 11 — evidence of biallelic inactivation. A SRSF2 p.Pro95Arg splice-factor mutation at 44.6 percent and two independent RUNX1 mutations completed a mutational triad that is a hallmark of CMML. A CEBPA nonsense mutation rounded out the profile. Together with sustained absolute monocytosis lasting more than three months and a flow-cytometric finding that 98 percent of the patient’s monocytes were of the classical CD14-positive, CD16-negative subset, the molecular data satisfied WHO and International Consensus Classification criteria for CMML-1 of the proliferative subtype.

Then came the third clone. Serum free light-chain testing showed lambda light chains elevated to 2,274.69 milligrams per liter against a kappa of just 28.98, crushing the kappa/lambda ratio to 0.0127 — roughly fiftyfold below the lower limit of normal. Immunofixation of serum and urine confirmed a monoclonal lambda component. Flow cytometry identified a lambda-restricted plasma-cell population, and fluorescence in situ hybridization on enriched CD138-positive cells revealed the t(11;14)(q13;q32) translocation fusing the immunoglobulin heavy-chain locus to CCND1, the cyclin D1 gene. Bone marrow biopsy showed at least 20 percent CD138-positive plasma-cell infiltration. Yet the team stopped short of calling it multiple myeloma: no myeloma-defining event was documented, since plasma cells remained below 60 percent, the involved/uninvolved light-chain ratio was about 78.5 rather than above 100, and PET-CT showed no focal bone lesions. They classified it conservatively as a t(11;14)-positive plasma-cell neoplasm under surveillance.

The biology behind this triple concurrency is what makes the case scientifically rich. Systemic mastocytosis with an associated hematologic neoplasm is itself not rare — roughly 30 to 40 percent of systemic mastocytosis patients harbor a second blood cancer, and CMML accounts for about a quarter to a third of those associations. The prevailing model holds that KIT D816V, TET2, and RUNX1 mutations arise in an early hematopoietic progenitor with multilineage potential, which then branches into mast-cell-dominant and monocyte-dominant subclones. This patient’s mutation profile — KIT D816V alongside TET2, SRSF2, and RUNX1 — fits that shared-ancestor model precisely. The plasma-cell disorder, however, is almost certainly an independent B-lineage event. Only isolated case reports have ever linked systemic mastocytosis with plasma-cell dyscrasias, and none have documented all three diseases simultaneously. Mechanistically, mast cells can secrete interleukin-6 and stem cell factor, cytokines known to support myeloma cell survival, and can engage CD40-CD154 signaling that promotes lymphoplasmacytic proliferation — possible, if speculative, links between the clones.

Treatment was tailored to the two clinically active components. The team initiated avapritinib, a potent and selective inhibitor of KIT D816V that overcomes the imatinib resistance conferred by that mutation, combined with azacitidine, a hypomethylating agent directed at the CMML clone and its TET2/SRSF2/RUNX1 signature. Venetoclax, which has shown activity in t(11;14)-positive myeloma, was deliberately withheld because the plasma-cell neoplasm had no documented myeloma-defining event and was not the immediate threat. After three cycles, the results were encouraging: the frequency of watery diarrhea decreased substantially, hemoglobin and platelet counts improved, the absolute monocyte count declined, and the alkaline phosphatase began trending downward. The authors note that overlapping myelosuppression from both drugs — azacitidine’s anemia, neutropenia, and thrombocytopenia, and avapritinib’s thrombocytopenia, bleeding risk, and cognitive effects — demanded careful monitoring. Serial light-chain measurements were unavailable during follow-up, so the plasma-cell clone’s response could not be formally assessed.

Beyond its rarity, the case is a pointed argument for diagnostic integration. No single abnormality in this patient could explain the full picture: the mast-cell disease accounted for the diarrhea and the alkaline phosphatase but not the monocytosis; the CMML explained the monocytes and cytopenias but not the lambda light chains; the plasma-cell clone explained neither the mast-cell burden nor the gastric hypermetabolism. Only by weaving together morphology, multiparameter flow cytometry, immunohistochemistry, FISH cytogenetics, and targeted sequencing could the team assemble three coherent diagnoses from one confusing clinical presentation. For clinicians, the lesson is that when a patient’s findings exceed what one hematologic disease can produce, the marrow — examined with every modern tool — may be hiding more than one answer.

Subject of Research: Coexistence of systemic mastocytosis, chronic myelomonocytic leukemia, and a t(11;14)-positive plasma-cell neoplasm in one patient

Article Title: Case Report: Coexistence of advanced systemic mastocytosis, chronic myelomonocytic Leukemia, and t(11;14)-positive plasma-cell neoplasm: a rare triple-clonal hematologic case

Article References: Yin, J., Luo, J., Huang, L., Wang, L., Zhong, M., Li, M., & Huang, S. (2026). Case Report: Coexistence of advanced systemic mastocytosis, chronic myelomonocytic Leukemia, and t(11;14)-positive plasma-cell neoplasm: a rare triple-clonal hematologic case. Frontiers in Oncology, 16, Article 1982665. https://doi.org/10.3389/fonc.2026.1982665

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1982665

Keywords: systemic mastocytosis, chronic myelomonocytic leukemia, plasma-cell neoplasm, KIT D816V, TET2, SRSF2, RUNX1, t(11;14), avapritinib, azacitidine, bone marrow diagnostics, SM-AHN

The study, published in the journal Pharmacia, is notable for what it did not use: the polished, idealized data of randomized clinical trials. Instead, researchers built their model on local real-world evidence drawn from 69 Bulgarian patients treated at the Specialized Hospital for Active Treatment of Hematological Diseases. Forty-nine patients received venetoclax plus azacitidine in a prospective cohort followed from 2022 to 2024, after venetoclax entered the national reimbursement lists, while 20 patients treated with azacitidine alone between 2018 and 2022 served as the comparator. By anchoring the azacitidine cohort in the pre-venetoclax era, the investigators deliberately avoided calendar-related bias, ensuring that both groups were treated within comparable modern clinical contexts.

All patients had newly diagnosed acute myeloid leukemia and were deemed ineligible for intensive chemotherapy for concrete clinical reasons: age of 75 or older, significant pulmonary or cardiac disease, liver cirrhosis, active resistant infection, poor functional status, kidney failure, or similar conditions. This is precisely the population in which treatment decisions carry the highest stakes and the least margin for error, and in which the balance between extending life and preserving its quality becomes most delicate.

Methodologically, the team constructed a one-year state-occupancy model with monthly cycles, dividing each patient’s trajectory into three mutually exclusive states: event-free survival, progressed or relapsed disease, and death. Rather than a full Markov transition model, which would have demanded stronger assumptions than the sparse progression data could justify, the researchers used a partitioned-survival-style approach in which monthly state proportions were derived directly from observed overall survival and reconstructed event-free survival. Progressed disease occupancy was calculated as the difference between the two survival curves, and death as one minus overall survival, with internal consistency checks ensuring that event-free survival never exceeded overall survival and that no state ever turned negative.

Quality of life entered the model through monthly patient responses to the EORTC quality-of-life questionnaire, mapped onto utility values using a published regression algorithm. Event-free patients carried a mean utility of 0.75, while those in progressed or relapsed disease averaged 0.63. Costs were tallied from the perspective of the Bulgarian National Health Insurance Fund and included drug acquisition, hospitalization, monitoring, diagnostic investigations, and supportive and palliative care, all priced at 2024 list prices and converted to euros at the fixed national exchange rate. Venetoclax acquisition alone cost roughly €9,760 per month, while azacitidine monotherapy ran about €2,802 monthly.

The base-case results were stark. Total yearly costs reached €99,532.86 per patient on the combination versus €44,344.09 on azacitidine alone, an incremental cost of €55,188.77. Against that expenditure, the combination delivered 0.51 quality-adjusted life-years versus 0.32, and 0.68 life-years versus 0.45, yielding incremental gains of 0.19 QALYs and 0.23 life-years. The resulting cost-effectiveness ratios were €289,309.59 per QALY gained and €235,736.28 per life-year gained, both far above Bulgaria’s accepted threshold of roughly €54,815, which corresponds to three times gross domestic product per capita.

Probabilistic sensitivity analysis using Monte Carlo simulation underscored how fragile the value proposition is at current prices. Only 4.4 percent of simulated cost-per-QALY estimates fell below the national threshold, and for cost per life-year gained the figure was 6.7 percent. The analysis suggested that the combination would only become acceptably cost-effective at a willingness-to-pay threshold of around €300,000, equivalent to more than twelve times GDP per capita, with results plateauing near €400,000. The model also faithfully captured the darker side of the therapy: some patients experienced severe adverse events during induction, and in certain simulations the combination produced negative quality-adjusted or even negative life-year gains, reflecting early treatment-related mortality.

One-way sensitivity analyses revealed that the results were most sensitive to the effectiveness of the combination itself. If venetoclax plus azacitidine delivered 30 percent lower QALYs or life-years than assumed, the cost per QALY soared past €1.5 million and the cost per life-year beyond €1.9 million. Yet the dispersion of probabilistic results clustered tightly around the base case for survival outcomes, suggesting that the survival benefit itself was relatively consistent, even as quality-of-life impacts varied more widely across patients.

Perhaps the most intriguing finding is how closely the Bulgarian real-world result mirrors trial-based economics from wealthier countries. The exploratory cost-utility ratio of roughly €289,000 per QALY aligns remarkably well with a United States estimate of $260,343 per QALY, lending incidental validation to the quality-of-life mapping algorithm the Bulgarian team employed. Meanwhile, first-year survival in the local cohort was numerically higher on the combination, and event-free survival was significantly better, indicating improved disease control even within a single year of follow-up. The authors contrast this with a real-world study in older, frailer patients where the combination was poorly tolerated, noting that their cohort’s median age of 71, close to Bulgarian life expectancy, may partly explain the difference.

The researchers are careful to frame their work as hypothesis-generating rather than reimbursement-grade. The sample of 69 patients is small, progression ascertainment was incomplete, the one-year horizon misses longer-term survival and late costs, and no external validation against larger multicenter datasets was yet possible. Longer time horizons in other analyses have pushed cost-effectiveness ratios down dramatically, to figures as low as $74,141 per life-year gained, suggesting that the true value of the combination may be substantially better than a one-year snapshot can capture. Still, the study delivers something Bulgaria has lacked: a transparent, locally grounded account of what this breakthrough therapy actually costs and delivers within its own health system. As venetoclax and similar targeted agents spread across Central and Eastern Europe, models like this one will become essential instruments for deciding which medical miracles a national payer can realistically afford, and at what price the arithmetic of hope must ultimately be settled.

Subject of Research: Cost-effectiveness of venetoclax plus azacitidine versus azacitidine monotherapy in Bulgarian patients with acute myeloid leukemia ineligible for intensive chemotherapy

Article Title: Exploratory cost-utility and cost-effectiveness analysis of venetoclax plus azacitidine vs. azacitidine monotherapy in Bulgarian patients with AML ineligible for intensive chemotherapy: a real-world-data-influenced state-occupancy model

Article References: Donchev, M., Davidkova, Y., Tachkov, K., & Petrova, G. (2026). Exploratory cost-utility and cost-effectiveness analysis of venetoclax plus azacitidine vs. azacitidine monotherapy in Bulgarian patients with AML ineligible for intensive chemotherapy: a real-world-data-influenced state-occupancy model. Pharmacia, 73, Article e197277. https://doi.org/10.3897/pharmacia.73.e197277

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e197277

Keywords: acute myeloid leukemia, venetoclax, azacitidine, cost-effectiveness, cost-utility analysis, QALY, real-world data, state-occupancy model, Bulgaria, health economics, pharmacoeconomics, National Health Insurance Fund

The case is notable because the patient had B-lymphoid/myeloid mixed phenotype acute leukemia, or MPAL, a biologically heterogeneous malignancy in which leukemic blasts simultaneously display features of both B-cell and myeloid lineages. MPAL accounts for only a small fraction of acute leukemias and carries an unfavorable prognosis. Standard treatment for younger adults typically involves intensive combination chemotherapy followed by consolidation, with or without allogeneic hematopoietic stem cell transplantation. But advanced age, comorbidities, and poor performance status often render older adults ineligible for both intensive chemotherapy and transplantation, leaving lower-intensity and targeted regimens as a critical unmet need.

The patient arrived at the Affiliated People’s Hospital of Ningbo University in March 2026 with a two-week history of fatigue and anorexia. His medical history was already formidable: chronic hepatitis B virus infection managed with long-term oral antiviral therapy, and lung adenocarcinoma initially treated with surgical resection followed by platinum-based chemotherapy. After the lung cancer relapsed, he underwent a second resection and received maintenance pembrolizumab for two years, ending in May 2025.

Laboratory investigations on admission revealed pancytopenia, a dangerous depletion of all three major blood cell lines. His leukocyte count was 0.6 × 10^9 per liter, his absolute neutrophil count 0.2 × 10^9 per liter, his hemoglobin 96 grams per liter, and his platelet count 73 × 10^9 per liter. Lactate dehydrogenase was elevated at 464 units per liter, fibrinogen was markedly elevated at 55.64 grams per liter, and D-dimer was significantly increased at 12,719 nanograms per milliliter, confirming disseminated intravascular coagulation, a life-threatening disorder in which the blood’s clotting system becomes catastrophically dysregulated.

Bone marrow aspiration morphology initially suggested acute myeloid leukemia, but multiparameter flow cytometry told a more complex story. Two distinct abnormal blast populations were identified. The first, comprising 38 percent of total nucleated cells, showed an aberrant B-cell precursor phenotype with expression of CD19, CD22, CD123, CD138, bright CD34, nuclear terminal deoxynucleotidyl transferase, and cytoplasmic CD79a. The second, at 21 percent, displayed an aberrant myeloid phenotype expressing CD19, CD123, CD38, CD34, CD117, and HLA-DR. Cytogenetic analysis revealed a complex karyotype with 78 to 83 chromosomes and multiple losses and structural abnormalities. Next-generation sequencing identified a TP53 missense mutation in exon 6 with a variant allele frequency of 68.67 percent, and a KIT missense mutation in exon 2 with a variant allele frequency of 72 percent. Both alterations were subsequently confirmed by whole transcriptome sequencing. Critically, the molecular test results were not available until day 10 after induction began, so they could not guide the initial therapeutic decision.

The team initiated a chemotherapy-free induction regimen: azacitidine at 100 milligrams intravenously daily for five days, dexamethasone at 10 milligrams intravenously daily for 14 days with subsequent tapering, and sonrotoclax with dose escalation beginning on day 4, stepping from 5 milligrams through 10, 20, 40, and 80 up to 160 milligrams. During this period, D-dimer levels peaked at 47,261 nanograms per milliliter, reflecting progressive disseminated intravascular coagulation with a markedly elevated hemorrhagic risk. Given this life-threatening complication, sonrotoclax was discontinued and supportive care with blood component transfusion was initiated.

On day 14 of the chemotherapy-free treatment, bone marrow evaluation revealed severe myelosuppression but no detectable residual leukemic cells. Blinatumomab was started on day 15 at 9 micrograms intravenously daily for one week, with planned dose escalation to 28 micrograms daily for the following week to deepen the remission. Supportive management included granulocyte colony-stimulating factor. No significant infections occurred during this period. Serial monitoring of HBV-DNA viral load showed no evidence of hepatitis B reactivation, a real concern given the patient’s chronic infection and the immunomodulatory nature of the treatment.

By day 28, complete hematologic recovery had been achieved, with normalization of leukocyte and platelet counts. Bone marrow examination confirmed remission with measurable residual disease negativity. The TP53 variant allele frequency had fallen to 2.460 percent, while the KIT variant allele frequency stood at 43.068 percent. The patient remains alive and has received consolidation therapy with the initial regimen. The authors note that given the previous platinum-based chemotherapy, the complex karyotype, and the TP53 mutation, therapy-related leukemia should be considered, but because pre-treatment peripheral blood or bone marrow samples from the lung-cancer phase were unavailable, further laboratory investigations to confirm the relationship could not be carried out.

The rationale for the triple-agent strategy draws on converging evidence from recent literature. Venetoclax combined with hypomethylating agents has demonstrated encouraging efficacy while sparing older patients the toxicity of intensive chemotherapy. Immunotherapeutic approaches are increasingly being explored in MPAL, and blinatumomab, a CD19/CD3 bispecific T-cell engager that physically links cytotoxic T cells to CD19-expressing leukemic cells, is effective in relapsed or refractory B-cell lineage MPAL, particularly when combined with venetoclax. Sonrotoclax, a novel second-generation BCL-2 inhibitor, offers superior BCL-2 binding affinity and selectivity and a lower risk of tumor lysis syndrome than venetoclax, potentially improving both efficacy and safety in hematological malignancies.

The authors emphasize that novel targeted agents and immunotherapies, alone or in combination, offer effective and tolerable alternatives for patients who cannot withstand conventional treatment. They call for prospective trials integrating genomic profiling, measurable residual disease-adapted therapy, and immunotherapeutic combinations to establish evidence-based standards for this population. As a single case report, the findings cannot establish the regimen as standard of care, and the durability of the remission remains to be seen. But for a disease where elderly patients have historically had few options beyond palliative care, the rapid, chemotherapy-free remission documented here offers a striking proof of principle that rational combinations of targeted and immune therapies can subdue even a genetically complex, dual-lineage leukemia.

Subject of Research: Chemotherapy-free targeted and immunotherapy combination for mixed phenotype acute leukemia in an elderly patient

Article Title: Chemotherapy-free treatment with azacitidine, short-course sonrotoclax and blinatumomab produces acute complete remission in B-lymphoid/myeloid mixed phenotype acute leukemia in an elderly patient: case report

Article References: Lin, Q., Lin, L., Du, X., Pei, R., & Lu, Y. (2026). Chemotherapy-free treatment with azacitidine, short-course sonrotoclax and blinatumomab produces acute complete remission in B-lymphoid/myeloid mixed phenotype acute leukemia in an elderly patient: case report. Frontiers in Hematology, 5, Article 1970481. https://doi.org/10.3389/frhem.2026.1970481

Image Credits: AI Generated

DOI: 10.3389/frhem.2026.1970481

Keywords: mixed phenotype acute leukemia, azacitidine, sonrotoclax, blinatumomab, BCL-2 inhibitor, chemotherapy-free treatment, TP53 mutation, disseminated intravascular coagulation, measurable residual disease, elderly patient, case report, hematology

The rationale behind the study is straightforward. In healthy individuals, the immature platelet fraction typically accounts for only a small percentage of all platelets, and it rises when the marrow is under pressure to replenish circulating platelets, for example after chemotherapy or in immune thrombocytopenia. In myelodysplastic syndromes, however, the marrow is intrinsically dysfunctional, and the relationship between platelet production and clinical outcome is far less predictable. If a high IPF reflects compensatory but ineffective platelet output, or if it signals biologically more aggressive disease, then the measurement might help clinicians identify patients at higher risk of leukemic transformation or death. Conversely, if the IPF adds nothing beyond established scoring systems, its clinical use would need to be reconsidered.

To address these questions, the researchers designed a two-part investigation. The retrospective arm drew on 364 patients with myelodysplastic syndromes whose baseline IPF values and clinical courses were available from hospital records. The prospective arm enrolled 46 patients under a registered observational protocol, identified as UMIN000057807, in whom the investigators followed outcomes forward in time with standardized assessments. The primary endpoint in both analyses was leukemia-free survival, a composite measure defined as the time until either transformation to acute myeloid leukemia or death from any cause. Secondary endpoints included overall survival and, among patients treated with the hypomethylating agent azacitidine, the rate of hematological improvement.

The retrospective results provided the first hint that the IPF might carry prognostic weight. Using a cutoff of 6.8 percent, the researchers divided the 364 patients into low and high IPF groups and found that 50 leukemia-free survival events occurred during follow-up. Patients whose baseline IPF exceeded 6.8 percent experienced significantly shorter leukemia-free survival and shorter overall survival in unadjusted analyses, with log-rank p values of 0.033 and 0.022 respectively. In a univariable model, a high IPF was associated with a hazard ratio of 1.79 for leukemia-free survival, meaning a roughly 79 percent increase in the risk of leukemic transformation or death, with a 95 percent confidence interval spanning 1.02 to 3.16.

Prognostic research, however, demands caution before celebrating any single variable, and the adjusted analyses told a more nuanced story. When the investigators controlled for age, platelet count, and the Revised International Prognostic Scoring System, a widely used risk stratification tool in myelodysplastic syndromes, the association retained a similar magnitude but lost statistical significance. The adjusted hazard ratio for leukemia-free survival was 2.02, with a 95 percent confidence interval of 0.98 to 4.18 and a p value of 0.057, sitting just at the threshold of conventional significance. The point estimate actually grew larger after adjustment, suggesting the IPF may capture information beyond standard scores, but the wide confidence interval reflects the limited number of events and leaves the conclusion uncertain. The discriminatory performance of the continuous IPF was likewise modest, with a two-year time-dependent area under the curve of 0.638 and a 95 percent confidence interval of 0.561 to 0.715, well short of the near-perfect separation clinicians would want from a standalone biomarker.

The study also probed the biological meaning of the IPF by comparing it with direct examination of the bone marrow. The continuous IPF value showed a moderate correlation with the bone marrow megakaryocyte count, quantified by a Spearman’s rank correlation coefficient of 0.50 with a p value below 0.001. Interestingly, however, the median megakaryocyte counts were identical across the high and low IPF groups, indicating that the correlation, while statistically robust, did not translate into a simple categorical distinction. This pattern suggests that the IPF reflects not merely how many megakaryocytes populate the marrow but how productively those cells release platelets, a functional dimension that conventional morphology may miss in dysplastic marrow.

The prospective cohort was intended to test these retrospective signals under more controlled conditions, and here the picture shifted. Among the 46 prospectively enrolled patients, overall survival and leukemia-free survival did not differ between those with an IPF at or below 6.8 percent and those above the threshold, with log-rank p values of 0.929 and 0.402 respectively. The explanation lies partly in the numbers: only three deaths and four leukemia-free survival events occurred in this small cohort, far too few to detect anything but a dramatic effect. Exploratory prospective studies of this size are inherently underpowered, and the absence of a difference should be read as inconclusive rather than as evidence that the IPF is prognostically irrelevant.

The azacitidine analysis added a therapeutic dimension to the investigation. Azacitidine, a hypomethylating agent, is a mainstay of treatment for higher-risk myelodysplastic syndromes, yet responses vary considerably between patients, and clinicians lack reliable predictors of who will benefit. Among response-evaluable patients treated with azacitidine, hematological improvement occurred in 4 of 14 patients, or 28.6 percent, in the high IPF group, compared with 5 of 8 patients, or 62.5 percent, in the low IPF group. The difference is striking in relative terms but did not reach statistical significance, with a p value of 0.187, and the tiny denominators make any interpretation speculative. Still, the direction of the effect raises the possibility that a high IPF, perhaps signaling more severely disordered thrombopoiesis, could be associated with reduced responsiveness to azacitidine, a hypothesis that only adequately powered trials can confirm or refute.

The authors are careful to frame the IPF as an investigational biomarker rather than a validated clinical tool, and their caution is warranted. The measurement itself is attractive: it is generated automatically by modern hematology analyzers using fluorescent dyes or equivalent technologies that stain RNA-rich reticulated platelets, requires no additional blood draw, and delivers results within the routine complete blood count workflow. Yet the present study demonstrates the classic challenges of biomarker research in rare malignancies. The retrospective signal was genuine but weakened after adjustment for established prognostic factors, the prospective cohort was too small to confirm or refute it, and the discriminatory capacity of the marker was modest at best. The investigators explicitly call for validation in adequately powered multicenter cohorts, which would allow event numbers sufficient for stable adjusted estimates and subgroup analyses across disease risk categories.

For patients and clinicians, the takeaway is one of tempered interest rather than immediate practice change. The immature platelet fraction is not yet ready to join the Revised International Prognostic Scoring System or molecular risk panels in guiding treatment intensity or transplant decisions. What the study does establish is a credible biological and statistical foundation for continued investigation: a plausible mechanism linking platelet turnover to disease behavior, a reproducible retrospective association, and a prospectively collected dataset that can inform the design of larger studies. As flow cytometry-derived and analyzer-derived markers of hematopoietic stress accumulate, the IPF may ultimately find its place alongside other measures in a composite prognostic model. Until such validation arrives, the 6.8 percent threshold remains a research cutoff, not a clinical decision point, and patients with myelodysplastic syndromes will continue to be risk-stratified by the established tools that decades of evidence have validated.

Subject of Research: Prognostic value of the immature platelet fraction in myelodysplastic syndromes

Article Title: The immature platelet fraction in myelodysplastic syndromes: retrospective associations and exploratory prospective cohort assessment

Article References: Yamasaki, S., Hashiguchi, M., Yoshida-Sakai, N., Jojima, H., Osaki, K., Okamura, T., & Imamura, Y. (2026). The immature platelet fraction in myelodysplastic syndromes: retrospective associations and exploratory prospective cohort assessment. Annals of Hematology. https://doi.org/10.1007/s00277-026-07270-z

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07270-z

Keywords: myelodysplastic syndromes, immature platelet fraction, biomarker, prognosis, azacitidine, acute myeloid leukemia, leukemia-free survival, thrombopoiesis, megakaryocytes, hematology, prospective cohort study, Revised International Prognostic Scoring System

The research, published in Annals of Hematology, took a direct approach to a question that has lingered at the edge of AML biology for years. Rather than inferring apoptotic behavior from broad molecular signatures, the team prospectively measured messenger RNA expression of apoptosis-related genes in bone marrow mononuclear cells from 90 patients with newly diagnosed AML. Every sample came from patients at the start of their treatment journey, before therapy could reshape the transcriptional landscape of their leukemia. That design choice matters, because it allowed the investigators to ask whether the apoptotic wiring present at diagnosis could predict what happened next — how long patients lived, how they responded to treatment, and whether their disease returned.

When the researchers clustered patients according to their apoptosis gene expression profiles, two biologically distinct groups emerged, and the differences between them were striking. The first cluster carried a transcriptional pattern that, on its surface, looked almost reassuring: relatively higher expression of the classic anti-apoptotic gene BCL2, the very gene targeted by one of modern hematology’s most celebrated drugs. The second cluster told a more complicated story. These patients showed coordinated upregulation of a battery of pro-apoptotic genes, including BCL2L11 (better known as BIM), BBC3 (PUMA), BID, BAD, BIK, and BAX — genes whose protein products are supposed to push cells toward self-destruction. At the same time, the cells appeared to shift their survival strategy away from BCL2 and toward alternative anti-apoptotic regulators, with increased expression of MCL1 and BCL2L1, which encodes the survival protein BCL-xL.

That combination — more pro-death genes, but a survival apparatus rebuilt around different guardians — might seem paradoxical, and the clinical outcomes made the paradox impossible to ignore. Patients in the second cluster had significantly inferior overall survival. The researchers also observed reduced expression of CASP3 and CASP7, the executioner caspases that carry out the final, irreversible steps of apoptosis, in this high-risk group. Lower levels of these molecular executioners, the authors suggest, may mean that even when the death signal is triggered, the cell’s machinery for completing the process runs less efficiently. In other words, the leukemic cells of Cluster 2 patients appeared to be shouting the commands for self-destruction while simultaneously dismantling the equipment needed to obey them.

The timing of the study gives its findings particular weight. The treatment of AML has been transformed in recent years by venetoclax, a BCL2 inhibitor that, when combined with the hypomethylating agent azacitidine — a regimen known as VenAza — has become a backbone of therapy for older patients and those unfit for intensive chemotherapy. Venetoclax works by neutralizing BCL2, removing one of the main shields that leukemic cells use to resist apoptosis. If a patient’s leukemia depends heavily on BCL2, the drug should work well. If the cells have quietly reorganized their survival machinery around MCL1 or BCL-xL, the drug’s leverage diminishes. The Lodz team’s data fit that logic with unsettling precision: among patients treated with venetoclax plus azacitidine, those in Cluster 2 demonstrated significantly shorter event-free survival.

The biological features of Cluster 2 help explain why. The researchers noted that this subgroup displayed a monocytic immunophenotype, a characteristic that previous studies had already associated with reduced sensitivity to BCL2-targeted therapy. Monocytic AML cells tend to rely more on MCL1 and other alternative survival proteins than on BCL2 itself, making venetoclax a less effective key for that particular lock. Combined with the transcriptional evidence of increased MCL1 and BCL-xL expression and diminished executioner caspase activity, the picture that emerges is of a leukemia subtype that is not merely more aggressive, but differently engineered — one whose apoptotic architecture is fundamentally less vulnerable to the therapies now widely deployed against it.

Then comes the study’s most provocative single finding. When the researchers examined individual genes rather than cluster-level patterns, one stood out: BIK. Higher BIK mRNA expression was associated with poorer survival and with a lack of response to venetoclax-azacitidine therapy, and the association held up as an independent prognostic marker. The paradox here is sharp. BIK is a pro-apoptotic gene, a member of the BH3-only family whose role is to help tip cells into death. Higher expression of a death-promoting gene should, intuitively, be good news. Instead, in this cohort, it flagged the patients most likely to fare badly. The authors highlight this paradoxical association explicitly, and it serves as a reminder that gene expression in cancer rarely obeys simple intuition — context, coordination, and the surrounding molecular machinery determine whether a signal means surrender or defiance.

Why might high BIK expression accompany worse outcomes? The study’s cluster-level data suggest a plausible framework. In Cluster 2, BIK is upregulated alongside a host of other pro-apoptotic genes as part of a broader transcriptional state, one in which the cell simultaneously bolsters alternative survival pathways through MCL1 and BCL-xL and dampens the caspase machinery that would finalize apoptosis. In that setting, elevated BIK may be less a weapon than a distress signal — a marker of a cellular state in which death pathways are chronically activated yet chronically thwarted. Cells locked in such a standoff may be under persistent stress, and stress-adapted leukemic cells are often the most difficult to eradicate. BIK expression, on this reading, is not causing the poor prognosis but faithfully reporting it, which is precisely what a good biomarker should do.

The clinical implications ripple outward in several directions. First, the study demonstrates that apoptosis-related gene expression, measured at diagnosis, defines clinically distinct AML subgroups — a finding that could eventually inform how patients are risk-stratified beyond the current arsenal of cytogenetic and mutation-based markers. Second, the link between Cluster 2 biology and shortened event-free survival on venetoclax-azacitidine raises the possibility that expression profiling of apoptotic genes could help identify, upfront, which patients are unlikely to benefit from the regimen and might be better served by alternative or combination strategies, including agents targeting MCL1 that are currently in development. Third, the independent prognostic value of BIK offers a concrete, testable candidate for prospective validation in larger and more diverse cohorts.

Cautious interpretation remains essential. The cohort comprised 90 patients treated at a single center, and the findings, while internally coherent, will need replication before they reshape clinical practice. The authors themselves frame the results as demonstrating that dysregulation of apoptosis-related gene expression defines clinically distinct subgroups and may contribute to differences in prognosis and therapeutic response — a claim about mechanism and association rather than a prescription for immediate changes in care. Yet the conceptual shift the study proposes is substantial. AML has traditionally been classified by the mutations its cells carry; this work argues that how those cells manage life and death — the balance of pro- and anti-apoptotic forces, the choice of survival protein, the integrity of the caspase execution machinery — is itself a meaningful axis of disease biology. If subsequent studies confirm the pattern, the humble measurement of apoptosis gene mRNA could become a routine part of the diagnostic conversation, and the paradoxical signal from BIK could stand as a symbol of how much remains to be learned about why some leukemias die on command and others simply will not.

Subject of Research: Apoptosis-related gene expression profiling in acute myeloid leukemia and its association with patient clustering, prognosis, and response to venetoclax-based therapy

Article Title: Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker

Article References: Strzałka, K., Strzałka, P., Jarych, D., Wiśnik, A., Mikulski, D., Kościelny, K., Czemerska, M., Zawlik, I., Wierzbowska, A., & Pluta, A. (2026). Apoptosis gene expression analysis identifies biologically distinct AML clusters and BIK as an independent prognostic marker. Annals of Hematology. https://doi.org/10.1007/s00277-026-07268-7

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07268-7

Keywords: acute myeloid leukemia, apoptosis, gene expression profiling, BIK, venetoclax, azacitidine, BCL2, MCL1, prognostic marker, drug resistance, caspases, hematology